Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iTEPsein: Immuno-PET with TF2 and 68Ga-IMP-288 in Breast Cancer
NCT01730612Phase 2Completed
- Sponsor
- CHU de Nantes
- Start
- Dec 2012
- Primary completion
- May 2017
- Modality
- Bispecific Antibodies, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
A Phase 2 trial of hMN-14 × m734, 68 Ga-IMP-288 in breast carcinoma, sponsored by CHU de Nantes. Started Dec 2012; status: completed.
02
Drugs
hMN-14 × m73468 Ga-IMP-288
03
Conditions
breast carcinoma
Beyond the preview
Go deeper on NCT01730612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01730612.